Omicia’s clinical next-generation sequencing (NGS) interpretation software will be used by Laboratory Corporation of America Holdings (LabCorp) for its clinical trials sequencing services. LabCorp’s testing services, combined with Omicia’s genome analysis platform, will allow the companies to provide a comprehensive suite of tools and services for incorporating genomic data into clinical trials.
Omicia’s software allows users to quickly and easily annotate genomes, analyze variant data and generate customized clinical reports for individual patients and research projects across a broad range of disease states and clinical trial designs. Customers also can store, analyze and manage their clinical trial data within a highly secure environment. Omicia provides a state-of-the-art genome analysis software suite using proprietary algorithms, scalable interpretation solutions, and curated pharmacogenomics modules and content, all within a secure, HIPAA-compliant analysis environment. Omicia also allows users to generate customizable clinical reports and accommodates various trial sizes and designs.
“Demand for well annotated and meaningful biomarker data to guide clinical trial design and execution is on the rise,” said Mike Aicher, Omicia’s CEO. “By integrating our breakthrough Opal genomic interpretation software with LabCorp’s clinical trials sequencing services into a complete and comprehensive solution, the analysis of genomic data can be easily and effectively integrated within clinical trials.”
The collaboration addresses the growing demand for NGS-derived biomarker data. The collaboration will enable customers of both companies to easily integrate NGS data into clinical trials and carry out studies quickly, efficiently and affordably.